

People with type 2 diabetes who already have established cardiovascular disease are at particularly high risk of future cardiovascular events – highlighting the importance of optimising their cardiovascular risk factor and diabetes management.

Your practice is invited to participate in a small group meeting activity. The meeting will focus on the prevention of cardiovascular events in people with type 2 diabetes who have established cardiovascular disease.

## Information and resources covered as part of this small group meeting

- ▶ An independent roundup of the latest evidence and guideline updates.
- ▶ Discussion on the pharmacological options available for glucose management in an increasingly complex primary care environment.
- ▶ Data about how this high-risk patient group is being managed in primary care
- ▶ Australian blood glucose treatment algorithm for type 2 diabetes and comparative drug table.

### Accreditations pending:

2 (Category 2) RACGP QI&CPD points

**Recognised as counting towards the  
Practice Incentives**

1 Core point in the ACRRM PD Program

**Program Quality Prescribing Incentive (PIP QPI)**

### BOOKING FORM

<p>Practice name: _____</p> <p>Practice address: _____</p> <p>Postcode: _____</p> <p>Phone: _____</p> <p>Fax: _____</p> <p>Email: _____</p>	<p>Contact name: _____</p> <p>Preferred contact method: Email <input type="checkbox"/> Phone <input type="checkbox"/> Fax <input type="checkbox"/></p> <p>Names of interested GPs: _____</p> <p>_____</p> <p>_____</p> <p>_____</p> <p>Please tick day and time preference</p>
---------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

This program is funded by Boehringer Ingelheim Pty Limited and Eli Lilly Australia Pty Limited and managed through VentureWise, a wholly owned commercial subsidiary of NPS MedicineWise. The program has been designed, developed and implemented by NPS MedicineWise with complete independence and editorial control and is based on best practice guidelines.

**TO OPT OUT** ☎ (02) 8217 8700 | 📠 02 9211 7578 | @info@nps.org.au